Aim:Cisplatin is one of the most known chemotherapeutic drugs which may lead to neurotoxicity. To our knowledge, agomelatine has not been investigated yet in the prevention of cisplatin-induced neuropathy.
Material and Methods:30 male albino Wistar rats with a range of weight of 285-300 grams were included in this study. Experimental animals were divided into three groups: healthy controls (HC, n=10), cisplatin group (CIS, n=10) and agomelatine plus cisplatin group (AC, n=10). Only cisplatin (EbeweLiba-Turkey) was administered to CIS group with a dose of 2.5 mg/kg. However, both agomelatine and cisplatin were administered to AC group. The animals were deceased by thiopental anesthesia and sciatic nerves were dissected. Then, we measured the levels of malondialdehyde (MDA), myeloperoxidase (MPO), total glutathione (tGSH) and superoxide dismutase (SOD) in the nerve tissue, and examined the sciatic nerve histopathologically.
Results:Mean levels of MDA, MPO, tGSH and SOD were 34.90(±13.83), 41.30(±18.03), 15.40(±6.06) and 48.60(±18.19); respectively. MDA and MPO were significantly lower in the AC group comparing to CIS group (p<0.001 and p<0.001, respectively). However, antioxidative parameters tGSH and SOD were significantly higher in AC group than CIS group (p<0.001 and p<0.001, respectively). Pathological examinations revealed that swelling of myelinated nerve fibers and evident myelin sheath degeneration were observed in CIS group.
Conclusion:We found that agomelatine decreased the oxidative status in cisplatin-treated rats. In AC group, myelin sheath degeneration was less than CIS group.
Full text PDF